Blau Farmacêutica S.A., a pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its medications cover various segments, such as immunology, oncology, nephrology, and infectology. The company provides injectable anesthetics; analgesics; oncological medicines and injectables; antivirals and antiretrovirals; acid pump inhibitor; antithrombotic; antirheumatic; antibiotics; medicines for hematopoietic organ; biopharmaceuticals; and biosimilars. It also offers biological drugs; specialized treatments for infectious diseases, special treatments, and others; and prescription and non-prescription drugs, including dermo-medicines, a full line of male condoms, and others for retail and non-retail markets. In addition, it provides blood products, biological, biotechnological, and muscle relaxants drugs. Further, it offers medicines related to gynecology, anticoagulants, gastroenterology, rheumatoid arthritis, and anemia. Additionally, it operates in plasma collection under the Hemarus banner. It serves hospitals, private clinics, chemotherapy and hemodialysis centers, and public health institutions. The company was incorporated in 1987 and is headquartered in Cotia, Brazil.
Metrics to compare | BLAU3 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLAU3PeersSector | |
---|---|---|---|---|
P/E Ratio | 7.6x | −6.5x | −0.7x | |
PEG Ratio | 0.28 | 0.00 | 0.00 | |
Price/Book | 1.0x | 5.5x | 2.6x | |
Price / LTM Sales | 1.2x | 42.4x | 3.4x | |
Upside (Analyst Target) | 28.5% | 246.7% | 37.6% | |
Fair Value Upside | Unlock | 23.2% | 5.3% | Unlock |